Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 10
Submit an article Journal homepage
7,702
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma

Manish A Shah1 Department of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY10021, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6913-9655View further author information
ORCID Icon,
Jaafar Bennouna2 Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, 44000, FranceView further author information
,
Toshihiko Doi3 Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, JapanView further author information
,
Lin Shen4 Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, ChinaView further author information
,
Ken Kato5 Department of Head & Neck Medical Oncology, National Cancer Center Hospital, Tokyo, 104-0045, JapanORCID Iconhttps://orcid.org/0000-0002-1733-5072View further author information
ORCID Icon,
Antoine Adenis6 Department of Medical Oncology, Institut du Cancer de Montpellier & IRCM, Inserm, Université Montpellier, ICM, Montpellier, 34298, FranceView further author information
,
Harvey J Mamon7 Department of Radiation Oncology, Brigham & Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA02115, USAView further author information
,
Markus Moehler8 Johannes Gutenberg University Clinic Mainz, Mainz, 55101, GermanyView further author information
,
Xiaolong Fu9 Shanghai Chest Hospital, Shanghai, 200025, ChinaView further author information
,
Byoung Chul Cho10 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 120-752, South KoreaView further author information
,
Sonal Bordia11 Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ07033, USAView further author information
,
Pooja Bhagia11 Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ07033, USAView further author information
,
Chie-Schin Shih11 Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ07033, USAView further author information
,
Anjali Desai11 Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ07033, USAView further author information
&
Peter Enzinger12 Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA02215-5450, USAView further author information
 show all
Pages 1143-1153 | Received 22 Sep 2020, Accepted 12 Nov 2020, Published online: 03 Feb 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.